Published Research & Validation Studies
Peer-reviewed evidence demonstrating our AI's clinical accuracy and real-world impact.
Feasibility of AI-Assisted Screening for Clinical Trials in Wet Age-Related Macular Degeneration
Lead Author: Louis Cai, MD - Retinal Diagnostic Center & Cosign AI
Study Design: 728 consecutive patient records from 6 retina specialists at Wills Eye Hospital and Retinal Diagnostic Center, validated across LUGANO/LUCIA (Eyepoint), ASCENT (REGENXBIO), and CONSTANCE (Genentech) trial criteria.
Key Findings:
- 97.1% overall accuracy across all three trial protocols
- Best performance on CONSTANCE trial: 98.8% accuracy, 100% sensitivity
- Average processing time: 167 seconds per patient
- Simultaneous screening across multiple trials demonstrated
Pain Management Practice Transformation
Partner: Cy-Pain and Spine Management
Implementation Results:
- Streamlined patient screening for therapeutic trials
- Improved documentation and clinical workflow
- Enhanced patient care coordination
- Reduced administrative burden on clinical staff
Impact: Demonstration of AI utility beyond ophthalmology, showing platform versatility for diverse therapeutic areas.
Read Full Case StudyActive Sponsor Partnerships
Leading sponsors are already using our technology to accelerate their clinical trials.
The Clinical Trial Delay Crisis
85%
of trials experience delays
$500K-800K
daily opportunity cost (Tufts CSDD)
$90M
potential revenue loss from 5-month delay
Recent Tufts CSDD studies suggest daily opportunity costs of $500,000-$800,000 in unrealized prescription drug sales, with 94% of delayed trials experiencing delays over one month.
Validated Across Multiple Trial Protocols
LUGANO/LUCIA
Eyepoint Pharmaceuticals
95.8% accuracy
ASCENT
REGENXBIO
96.6% accuracy
CONSTANCE
Genentech
98.8% accuracy
All three trials focused on wet age-related macular degeneration therapeutics